Literature DB >> 10473112

Adenovirus-mediated E2F-1 gene transfer inhibits MDM2 expression and efficiently induces apoptosis in MDM2-overexpressing tumor cells.

H L Yang1, Y B Dong, M J Elliott, T J Liu, C Atienza, A Stilwell, K M McMasters.   

Abstract

The oncoprotein MDM2 binds and inactivates p53. MDM2 also binds to the tumor suppressor pRB, as well as E2F-1. E2F-1 is a transcription factor that regulates S phase entry and has been shown to cause apoptosis in some cell types when overexpressed. To investigate the effect of adenovirus-mediated E2F-1 overexpression, MDM2-overexpressing tumor cell lines were treated by mock infection, infection with an adenoviral vector expressing beta galactosidase, or E2F-1 (Ad5CMV-E2F-1). Western blot analysis confirmed significant overexpression of E2F-1 in Ad5CMV-E2F-1-infected cells. E2F-1 overexpression resulted in marked growth inhibition and rapid loss of cell viability. Ad5CMV-E2F-1 infection resulted in early S phase entry, followed by apoptotic cell death. E2F-1 overexpression was associated with a marked decrease in MDM2 levels and no evidence of increased Bax levels, whereas p53 and Bcl-2 levels remained undetectable. Cleavage of poly-ADP-ribose polymerase and caspase 3/CPP32 implicated activation of the caspase cascade in E2F-1-mediated apoptosis. These results indicate that adenovirus-mediated E2F-1 overexpression in MDM2-overexpressing tumor cells results in decreased MDM2 expression and widespread apoptosis. Because MDM2-overexpressing tumors are often resistant to p53 gene therapy, adenovirus-mediated E2F-1 gene therapy may be a promising alternative strategy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10473112

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  7 in total

1.  Enhanced cancer cell killing by truncated E2F-1 used in combination with oncolytic adenovirus.

Authors:  Jorge G Gomez-Gutierrez; Xiao-Mei Rao; Heshan Sam Zhou; Kelly M McMasters
Journal:  Virology       Date:  2012-09-27       Impact factor: 3.616

2.  BH3-based fusion artificial peptide induces apoptosis and targets human colon cancer.

Authors:  Yongjun Liu; Yunfeng Li; Haijuan Wang; Jing Yu; Hongwei Lin; Dongkui Xu; Yang Wang; Ailing Liang; Xiao Liang; Xueyan Zhang; Ming Fu; Haili Qian; Chen Lin
Journal:  Mol Ther       Date:  2009-04-07       Impact factor: 11.454

3.  Transcriptional repression of the prosurvival endoplasmic reticulum chaperone GRP78/BIP by E2F1.

Authors:  Tomás Racek; Sven Buhlmann; Franziska Rüst; Susanne Knoll; Vijay Alla; Brigitte M Pützer
Journal:  J Biol Chem       Date:  2008-10-07       Impact factor: 5.157

4.  Antisense MDM2 enhances E2F1-induced apoptosis and the combination sensitizes androgen-sensitive [corrected] and androgen-insensitive [corrected] prostate cancer cells to radiation.

Authors:  Thirupandiyur S Udayakumar; Paul Hachem; Mansoor M Ahmed; Sudhir Agrawal; Alan Pollack
Journal:  Mol Cancer Res       Date:  2008-11       Impact factor: 5.852

5.  NSP 5a3a: a potential novel cancer target in head and neck carcinoma.

Authors:  Luca D'agostino; Antonio Giordano
Journal:  Oncotarget       Date:  2010-10

Review 6.  Targeting the cell cycle for cancer therapy.

Authors:  A Carnero
Journal:  Br J Cancer       Date:  2002-07-15       Impact factor: 7.640

Review 7.  E2F1 death pathways as targets for cancer therapy.

Authors:  B M Pützer
Journal:  J Cell Mol Med       Date:  2007 Mar-Apr       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.